Clinical Trials Directory

Trials / Conditions / Relapsed Hematologic Malignancy

Relapsed Hematologic Malignancy

11 registered clinical trials studyying Relapsed Hematologic Malignancy — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Phase 1
RecruitingPRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
NCT05956457
Pack HealthN/A
RecruitingLong-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
NCT05713214
St. Jude Children's Research Hospital—
RecruitingInternational Leukemia Target Board
NCT05270096
Princess Maxima Center for Pediatric Oncology—
WithdrawnA Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
NCT05205252
Epizyme, Inc.Phase 1 / Phase 2
UnknownImpact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist o
NCT04327583
Institut Cancerologie de l'OuestN/A
UnknownInfusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploid
NCT03821519
A.O. Ospedale Papa Giovanni XXIIIPhase 1 / Phase 2
UnknownA Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
NCT03560882
Joaquina BarandaPhase 1
Active Not RecruitingLen/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
NCT03413800
Ciusss de L'Est de l'Île de MontréalPhase 2
RecruitingCA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractor
NCT03328078
Curis, Inc.Phase 1 / Phase 2
CompletedExtended Analysis for Leukemia/Lymphoma Treatment
NCT03096821
Medical University of Vienna—